IceCure Medical (NASDAQ:ICCM) Stock Price Down 3.1% - Should You Sell?

IceCure Medical Ltd (NASDAQ:ICCM - Get Free Report)'s stock price fell 3.1% during mid-day trading on Monday . The company traded as low as $1.09 and last traded at $1.09. 107,900 shares were traded during mid-day trading, a decline of 77% from the average session volume of 467,094 shares. The stock had previously closed at $1.13.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and issued a $2.50 price objective on shares of IceCure Medical in a research note on Friday, March 28th.

IceCure Medical Stock Performance

The stock's 50-day moving average is $1.26 and its 200 day moving average is $1.06. The stock has a market cap of $66.32 million, a price-to-earnings ratio of -4.12 and a beta of 0.43. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.67 and a quick ratio of 2.27.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. The business had revenue of $1.07 million for the quarter, compared to analysts' expectations of $1.07 million. As a group, analysts predict that IceCure Medical Ltd will post -0.28 earnings per share for the current fiscal year.

Institutional Trading of IceCure Medical

A hedge fund recently raised its stake in IceCure Medical stock. Geode Capital Management LLC raised its holdings in IceCure Medical Ltd (NASDAQ:ICCM - Free Report) by 58.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,453 shares of the company's stock after purchasing an additional 14,893 shares during the period. Geode Capital Management LLC owned 0.07% of IceCure Medical worth $44,000 at the end of the most recent reporting period. Institutional investors own 0.62% of the company's stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.